Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Titan Pharma (TTNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine...

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals Reports First Quarter 2018 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals To Report First Quarter 2018 Financial Results On May 15, 2018

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 2, 2018 / Titan Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 2, 2018 at 4:15 PM Eastern Time....

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

SOUTH SAN FRANCISCO, Calif. , April 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases...

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 1.04 (-4.59%)
Data Shows That the Global Addiction Treatment Market is Set to Grow

Data provided by Transparency Market Research, indicates that global addiction treatment market was valued at approximately US$ 4.0 billion in 2016 and is anticipated to expand at a CAGR of over 6.0% from...

BICX : 0.1300 (-0.08%)
DRRX : 1.95 (-1.52%)
TTNP : 1.04 (-4.59%)
BDSI : 3.10 (+6.90%)
EGLT : 0.44 (unch)
Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories

SOUTH SAN FRANCISCO, Calif. , March 21, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has entered into a definitive asset purchase, supply and support agreement...

TTNP : 1.04 (-4.59%)
Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has entered into a definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio...

TTNP : 1.04 (-4.59%)
Biotechnology and Substance Abuse Markets Have Positive Projections

According to data published by Grand View Research, Inc. the global biotechnology market is projected to reach a value of USD 727.1 billion by 2025. Major technological developments in segments such as...

BICX : 0.1300 (-0.08%)
DRRX : 1.95 (-1.52%)
TTNP : 1.04 (-4.59%)
EGLT : 0.44 (unch)
RGLS : 0.69 (+1.93%)
Global Substance Abuse and Addiction Treatment Market Projected to Grow

According to a report by BCC research the global substance abuse and addiction treatment market has the potential to reach $4.4 billion annually by 2021. The main reason for the global rise in substance...

IMUC : 0.26 (-2.62%)
BICX : 0.1300 (-0.08%)
ELTP : 0.0892 (-3.57%)
DRRX : 1.95 (-1.52%)
TTNP : 1.04 (-4.59%)
Titan Announces Amendment To Horizon Loan Agreement

SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing...

TTNP : 1.04 (-4.59%)
Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization

SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases...

TTNP : 1.04 (-4.59%)
Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals Reports Third Quarter 2017 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals Schedules Conference Call To Review Third Quarter 2017 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 1.04 (-4.59%)
Titan Pharmaceuticals Presents Non-Clinical Data From Liothyronine (L-T3) Implant Studies

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced today the planned presentation of non-clinical data on the use of its ProNeura(TM) subdermal implant for the long-term, sustained delivery of liothyronine...

TTNP : 1.04 (-4.59%)
Featured Company News - Titan Pharmaceuticals Announces First Patient Treatment for Parkinson's Disease in Phase-1/2 Trial with Ropinirole Implant

Research Desk Line-up: Merus Post Earnings Coverage

TTNP : 1.04 (-4.59%)
MRUS : 22.06 (-1.82%)
First Patient Treated With Titan Pharmaceuticals' Subdermal Implant For Parkinson's Disease

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 1.04 (-4.59%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -2.19 , FTNT -0.81 , CAKE -2.16 , PLT -0.20 , AEO -0.88
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed Friday steady to fractionally mixed, as July was down 1.11% on the week. The USDA reported a private export sale of 131,300 MT of corn to Mexico this morning. The sale was broke down to 30,000 MT for delivery in 2017/18, with the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar